×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
3 Reasons to Buy AbbVie Stock on the Dip
The Motley Fool
It's been more than a year since AbbVie (ABBV 1.85%) lost patent exclusivity for its most important product, Humira, an immunology medicine.
16 hours ago
AbbVie Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge ...
AbbVie News Center
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across...
5 days ago
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC
AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on...
4 days ago
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
Yahoo Finance
AbbVie's acquisition of ImmunoGen strengthens its oncology pipeline and solid tumor capabilities. Robust financial performance with $12.3...
2 days ago
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
BioSpace
Boehringer Ingelheim on Wednesday won the FDA's approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo,...
3 days ago
3 Reasons to Buy AbbVie Stock on the Dip
sharewise
It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine.
9 hours ago
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters
AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit...
1 week ago
AbbVie Reports First-Quarter 2024 Financial Results
PR Newswire
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1...
1 week ago
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
Investopedia
AbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will continue to lose market share to biosimilars.
1 week ago
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
Morningstar
We are holding our fair value estimate for AbbVie ABBV steady following its largely in-line first-quarter results. The company continues to...
1 week ago